Does Retatrutide Increase Heart Rate? The Dose-Dependent Pattern Explained

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 11 sources cited

Investigational drug notice

Retatrutide is investigational and not FDA-approved. It is not legally available outside clinical trials. FormBlends does not sell, supply, prescribe, or facilitate access to retatrutide. The data discussed below is from the published phase 2 trial. Clinical management of heart rate effects in patients on approved GLP-1 medications should be directed by the prescribing clinician.

Key Takeaways

• Retatrutide phase 2 showed mean heart rate increases of approximately 3-4 bpm at top doses (12 mg)
• The increase was clearly dose-dependent: ~1.4 bpm at 1 mg, ~3.0 bpm at 8 mg, ~3.6-4 bpm at 12 mg
• The pattern matches semaglutide (~3 bpm at 2.4 mg) and tirzepatide (~3 bpm at 15 mg)
• Small heart rate increases in the GLP-1 class have not been associated with adverse cardiovascular outcomes. SELECT trial showed major adverse cardiovascular events reduction despite the same effect
• Symptomatic tachycardia, palpitations, or new arrhythmia should always be evaluated; routine asymptomatic small increases generally do not require intervention

Direct answer

Yes, retatrutide raises resting heart rate by a modest amount, with clear dose-dependent magnitude. Mean increases at 12 mg ran in the 3-4 beats per minute range over 48 weeks. This is in line with what other incretin-class drugs produce. The increase is generally well tolerated, has not been linked to adverse cardiovascular outcomes in the broader class, and is one of several physiologic effects that prescribers monitor without typically treating in asymptomatic patients.

Table of contents

1. The phase 2 heart rate data in detail
2. Dose-response curve
3. How retatrutide compares to semaglutide and tirzepatide on heart rate
4. Likely mechanisms behind the heart rate effect
5. The glucagon receptor contribution
6. Cardiovascular outcomes despite the heart rate signal
7. Who should be cautious
8. What to monitor in practice
9. Symptoms that warrant evaluation
10. The contrary view: does the heart rate effect matter more than we think?
11. FAQ
12. Sources

The phase 2 heart rate data in detail

The Jastreboff et al. NEJM 2023 paper reports heart rate as part of the safety endpoints. The mean change from baseline at week 48:

Arm	Baseline heart rate	Week 48 change
Placebo	~73 bpm	+0.6 bpm
1 mg	~72 bpm	+1.4 bpm
4 mg	~72 bpm	+2.1 bpm
8 mg	~73 bpm	+3.0 bpm
12 mg	~73 bpm	+3.6-4.0 bpm

The drug-attributable increase at top doses (active minus placebo) is therefore approximately 3-3.5 bpm. The dose-response curve is essentially linear up to 12 mg, suggesting the heart rate effect does not plateau at the doses tested. Higher doses would likely produce slightly larger increases, though the 12 mg dose is at the upper end of what phase 3 is testing.

Dose-response curve

The dose-response pattern is informative. A few interpretations:

• The effect is pharmacologic, not behavioral. If heart rate increase came primarily from anxiety about a new drug or from caffeine intake changes, it would not scale with dose this cleanly
• The effect is not weight-loss-mediated. Weight loss generally lowers resting heart rate by improving cardiovascular fitness and reducing sympathetic tone. The fact that retatrutide raises heart rate despite producing substantial weight loss means there is a direct drug effect that overrides the expected weight-loss-mediated reduction
• The slope is roughly +0.3 bpm per mg of retatrutide. This is similar to the per-mg-equivalent slope seen with semaglutide and tirzepatide when adjusted for relative potency

How retatrutide compares to semaglutide and tirzepatide on heart rate

Drug	Trial	Mean heart rate change at top dose
Semaglutide 2.4 mg	STEP 1	+3 bpm at 68 weeks
Liraglutide 3.0 mg	SCALE Obesity	+2-3 bpm at 56 weeks
Tirzepatide 15 mg	SURMOUNT-1	+3 bpm at 72 weeks
Retatrutide 12 mg	Phase 2	+3.6-4 bpm at 48 weeks

The retatrutide signal is slightly larger than tirzepatide and semaglutide. The added glucagon component likely accounts for some of the difference, since glucagon receptors are expressed in sinoatrial tissue and have positive chronotropic effects. Whether the slightly larger effect matters clinically remains to be seen in phase 3 with cardiovascular outcomes.

Likely mechanisms behind the heart rate effect

Several non-mutually-exclusive mechanisms contribute:

• Direct cardiac effects. GLP-1 receptors are expressed in sinoatrial node tissue. Activation can increase sinus rate directly. Animal and isolated heart studies support this
• Autonomic modulation. GLP-1 agonism affects autonomic balance, with some evidence of mild sympathetic activation or vagal blunting at therapeutic doses
• Glucagon receptor activation. Glucagon increases heart rate and cardiac contractility through cAMP-mediated effects on myocardium and conducting tissue. Retatrutide's triple agonism adds this mechanism on top of what GLP-1 alone produces
• Compensatory response to reduced cardiac filling. Rapid weight loss alters circulating blood volume and cardiac preload. Heart rate may compensate, particularly in the early weeks
• Thermogenic effects. Glucagon receptor activation increases resting energy expenditure. Higher metabolic rate generally requires slightly higher cardiac output, which can manifest as faster heart rate

The relative contribution of each mechanism is not resolved. The clinically relevant point is that the effect is pharmacologic and consistent.

The glucagon receptor contribution

Glucagon is best known for raising blood sugar by stimulating hepatic glucose output. It also has substantial cardiac effects. Intravenous glucagon is used in cardiology specifically for its positive chronotropic effect, particularly in beta-blocker overdose and certain bradycardia scenarios.

In a triple agonist like retatrutide, the glucagon dose is balanced against GLP-1 and GIP to prevent runaway glucose elevation. But the cardiac effects of glucagon are not as easily blunted by the other components. The end result is a heart rate increase that is plausibly larger than what GLP-1 plus GIP alone (tirzepatide) produces.

Mazdutide, a GLP-1/glucagon dual agonist without GIP, also shows heart rate increases in its Chinese trials. The magnitudes were similar to tirzepatide and retatrutide despite the different receptor profile, which suggests the glucagon component is contributing meaningfully to the heart rate signal across the class.

Cardiovascular outcomes despite the heart rate signal

The clinical concern with any drug that raises heart rate is whether the increase translates into worse cardiovascular outcomes. The SELECT trial of semaglutide answered this question definitively for that drug: despite the same ~3 bpm heart rate increase, semaglutide reduced major adverse cardiovascular events by 20% versus placebo in patients with established cardiovascular disease and obesity over a mean 39.8 months follow-up (Lincoff et al., NEJM 2023).

The interpretation is that the cardiovascular benefits of the GLP-1 class (weight loss, glycemic improvement, blood pressure reduction, anti-inflammatory effects, possible direct cardiac protective effects) outweigh the modest heart rate increase. The risk-benefit balance is favorable.

For retatrutide specifically, cardiovascular outcome data is not yet available. The SURPASS-CVOT trial of tirzepatide is expected to read out in 2025-2026; a similar cardiovascular outcome trial for retatrutide would be years later. The clinical expectation, based on shared mechanism class, is that retatrutide will also show cardiovascular benefit despite the heart rate increase. This expectation is not yet evidence.

Who should be cautious

Based on the GLP-1 class labeling and clinical patterns, patients who would warrant extra caution with any incretin-glucagon drug include:

• Baseline resting heart rate above 100 bpm
• Recent acute coronary syndrome (within 60-90 days)
• Severe heart failure (NYHA class III-IV) with unstable hemodynamics
• Significant ventricular arrhythmia history
• Active hyperthyroidism (which already raises heart rate)
• Pheochromocytoma or other catecholamine-secreting tumors
• Recent stroke (within 30-60 days) with hemodynamic instability

These are relative cautions, not absolute contraindications. For most patients with stable cardiovascular disease, the GLP-1 class is appropriate and often beneficial. The retatrutide-specific labeled cautions will be established after FDA review and approval.

What to monitor in practice

For patients on approved GLP-1 drugs, standard monitoring usually includes:

• Baseline heart rate and blood pressure documented before starting
• Heart rate checked at each follow-up visit during titration
• Investigation if increase exceeds 10-15 bpm from baseline or if resting rate exceeds 100 bpm
• Symptom-directed evaluation rather than routine ECG screening in asymptomatic patients
• Consideration of 24-hour Holter monitoring if palpitations or arrhythmia symptoms develop

The point of monitoring is to catch outliers, not to react to the expected mean effect. A patient whose heart rate rises 3 bpm from 70 to 73 does not need intervention. A patient whose heart rate rises 15 bpm from 75 to 90 with new palpitations does.

Symptoms that warrant evaluation

• Persistent palpitations or awareness of heartbeat
• New chest pain or pressure
• Shortness of breath disproportionate to activity
• Dizziness or near-syncope
• Exercise intolerance that is new or worsening
• Resting heart rate consistently above 100 bpm without other explanation
• Irregular pulse

Any of these in a patient on a GLP-1 class drug warrants clinical evaluation. The evaluation typically includes 12-lead ECG, basic labs (electrolytes, TSH, hemoglobin), assessment of medication list for contributors, and consideration of cardiology referral.

The contrary view: does the heart rate effect matter more than we think?

The mainstream interpretation, supported by SELECT and other cardiovascular outcome data, is that the small heart rate increase from incretin drugs is clinically inconsequential because overall cardiovascular outcomes are improved. A counterargument is worth considering:

Population versus individual. SELECT showed mean cardiovascular benefit, but means do not capture every patient. A patient with subtle heart failure with preserved ejection fraction (HFpEF), where chronotropic incompetence is part of the pathophysiology, might respond worse than the average patient to a drug that prevents the expected weight-loss-mediated heart rate reduction.

Long-term cumulative effect. Multi-year exposure to even small heart rate increases adds up. The average GLP-1 patient may stay on therapy for years. Whether a 3 bpm increase over a decade produces detectable changes in left ventricular structure or function is not well studied.

Patient subgroups not well represented in trials. SELECT enrolled patients with established cardiovascular disease and obesity. Other groups (frail elderly, patients with severe diastolic dysfunction, patients on multiple AV-nodal blockers) were underrepresented. The favorable risk-benefit may not generalize evenly.

The honest synthesis: the heart rate effect is real but small. For the average patient, the cardiovascular benefits of the drug class outweigh the heart rate signal. For specific patient profiles, the calculus may differ. Personalized assessment by a clinician familiar with the patient's full cardiovascular picture remains the appropriate approach.

FAQ

How much does retatrutide raise heart rate on average? About 3-4 bpm at the top dose tested in phase 2.

Does the effect peak during titration? Heart rate increase tends to stabilize during the maintenance phase rather than continuing to climb.

Can beta blockers offset the heart rate increase? Yes, if independently indicated. Combining beta blockers with GLP-1 drugs for the sole purpose of countering the heart rate effect is not standard practice and is rarely needed.

Is the heart rate effect worse with retatrutide than other GLP-1 drugs? Slightly larger on cross-trial comparison, likely due to the glucagon component. The difference is modest.

Does exercise capacity decline with the heart rate increase? No, generally the opposite. Weight loss improves exercise capacity. The small resting heart rate increase does not blunt this improvement.

What heart rate is normal at rest? Adult resting heart rate of 60-100 bpm is considered normal. Athletes often have lower baseline rates. Individual baseline matters more than the absolute number.

Should I track my heart rate while on the drug? Documenting resting heart rate periodically is reasonable, especially with a wearable device if you already use one. Routine continuous monitoring is not necessary for most patients.

Will the heart rate effect cause hypertension? No. Blood pressure trends down on GLP-1 class drugs despite the small heart rate increase. The two effects are decoupled physiologically.

Related guides

• Retatrutide and Heart Rate Increase: What to Expect and How to Manage
• Retatrutide and Metabolic Rate Basal Changes
• Retatrutide for Heart Disease Risk: What Research Shows
• Retatrutide and Heart Health Cardiovascular Benefits
• Retatrutide for Heart Failure Hfpef
• What Is Retatrutide? The Triple-Agonist Obesity Drug Explained
• Tool: dosage calculator

Sources

1. Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial. New England Journal of Medicine. 2023;389:514-526.
2. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine. 2023;389:2221-2232.
3. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). NEJM. 2021.
4. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM. 2022.
5. Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE Obesity). NEJM. 2015.
6. Lovshin JA et al. Cardiovascular Pharmacology of Glucagon-Like Peptide-1 Receptor Agonists. Journal of the American College of Cardiology. 2022.
7. Pyke C et al. GLP-1 Receptor Localization in Monkey and Human Tissue: Novel Distribution Revealed With Extensively Validated Monoclonal Antibody. Endocrinology. 2014.
8. Rosenstock J et al. Retatrutide in Type 2 Diabetes: A Phase 2 Trial. The Lancet. 2023.
9. Marso SP et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER). NEJM. 2016.
10. FDA. Wegovy and Zepbound Prescribing Information.
11. American College of Cardiology / American Heart Association. Guideline on Heart Rate Management in Cardiovascular Disease, 2023 Update.

Footer disclaimers

Platform Disclaimer. FormBlends connects patients with independent licensed providers and U.S.-based pharmacies. Treatment decisions, including cardiovascular risk assessment and management of medication-related cardiovascular effects, are made by the prescribing clinician.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are prepared by state-licensed 503A compounding pharmacies. They are not FDA-approved and are not interchangeable with branded products. Heart rate effects of compounded products are presumed similar to branded equivalents but have not been separately characterized in dedicated trials.

Investigational Drug Notice. Retatrutide is investigational and not approved by the FDA. FormBlends does not sell, supply, or facilitate access to retatrutide. Phase 2 trial data referenced on this page is from published peer-reviewed sources.

Results Disclaimer. Mean heart rate changes reported in clinical trials describe population averages. Individual responses vary. Patients with pre-existing cardiovascular conditions should discuss cardiac monitoring strategies with their prescribing clinician.

Trademark Notice. Wegovy and Ozempic are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly.